However, it was only after switching treatment to the ileal bile acid transporter (IBAT) inhibitor odevixibat at three months of age, that the patient exhibited significant improvement, including normalization of cholestasis parameters and liver enzymes. The gene discussed is SLC10A2; the disease is cholestasis.